KROLL-ONTRACK
26.1.2016 13:48:07 CET | Business Wire | Press release
Amid global legal changes which affect the transfer of data between countries and in regulated industries, organisations are grappling with how best to address data privacy concerns when dealing with investigations, regulatory demands for information and compliance requirements. In response, Kroll Ontrack has today launched a unique service delivery model combining portable ediscovery technologies and consultancy, empowering organisations to capture, analyze, process, filter and review data anywhere.
Kroll Ontrack’s mobile solution combines powerful processing and review technologies, with local consultative expertise to enable onsite filtering, examination and review of data – without the need for a data center or a fixed, in-country solution. Kroll Ontrack’s computer forensic and investigations experts conduct targeted data analysis and work side-by-side with compliance, ediscovery teams lawyers to home in on specific user activity and formulate fact-based case strategies, on location.
“The power, portability and flexibility of our mobile solution has accelerated our ability to help global clients address global data challenges, literally anywhere,” says Wendy King, product director, Kroll Ontrack. “In the last six months, we have seen a significant increase in clients needing assistance with complex, often sensitive investigations in regions or industries with restrictive privacy laws or complicated regulations. Our integrated global solution, deployed by consultants who are familiar with local laws, languages and cultural issues, gives our clients access to powerful technology and local expertise wherever and whenever they need them.”
Today, ediscovery is becoming an important element of the business and corporate governance landscape, even for countries that do not have an obligation to carry out ediscovery under their legal framework. A recent New Frontiers in Ediscovery report by Kroll Ontrack notes the rapid growth of ediscovery across Europe and Asia and highlights the adaptability of ediscovery technology, which is now used in a wealth of legal scenarios and not just limited to litigation cases.
“Global organizations and law firms are turning to versatile ediscovery technologies to handle a wide range of data management situations,” said Mark Williams, CEO, Kroll Ontrack. “Specifically, mobile technology partnered with local consultative expertise can be a cornerstone for better understanding a dataset, whether investigating fraud and corruption around the globe, handling litigation data in highly regulated environments, industries or countries, or retrieving highly sensitive company data internationally or domestically”.
Tim Phillips, Managing Director of Kroll Ontrack International Legal Technologies, said: “The recent invalidation of the Safe Harbor regime, General Data Protection Regulation reform in the EU, and China State Secrecy laws are forcing organisations to tighten their data management practices and seek tangible solutions such as mobile ediscovery to address data privacy challenges.”
Demand from clients all over the world for local expertise and support has driven the expansion of Kroll Ontrack’s global network of data centers and document review teams. In addition to Kroll Ontrack’s mobile solution and five data centers (US, UK, France, Germany, Japan), Kroll Ontrack has 30 offices around the globe with jurisdictional expertise to support a truly global service offering. As well as opening its German data center in Frankfurt in May 2014, Kroll Ontrack launched its French data center in Paris earlier in 2015 along with its highly successful and fast-growing document review center in London’s legal district in January 2015. Since the end of 2015 Kroll Ontrack has been providing teams of project lawyers for document review, either in their document review centers in Böblingen,and Frankfurt or at their client’s premises. Most recently, Kroll Ontrack announced the offering of ediscovery services in China to help clients observe State Secrecy laws and the integration of Relativity into its UK offering , with plans to launch Relativity into its Tokyo environment in March of 2016. Kroll Ontrack is a Relativity Best in Service partner and won the 2015 Relativity Innovation Award for Best Service Provider Solution.
For more information on Kroll Ontrack’s mobile solutions, please visit: http://www.ediscovery.com/uk/solutions/mobile-solution/
About Kroll Ontrack LLC
Kroll Ontrack provides technology-driven services and solutions to help legal, corporate and government entities as well as consumers manage, recover, search, analyse, review and produce data efficiently and cost-effectively. In addition to its award-winning suite of software, Kroll Ontrack provides data recovery, data destruction, electronic discovery, consulting and document review. For more information about Kroll Ontrack and its offerings please visit: http://www.ediscovery.com/uk or follow @KrollOntrack on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160126005828/en/
Contact:
Citigate Dewe Rogerson for Kroll Ontrack
Judith Massey, Charlotte
Pascal, Camilla Medd
Tel: 00 +44 (0) 207 638 9571
Camilla.medd@citigatedr.co.uk
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom